Dr. Selwyn Ho is an experienced biopharma and biotech executive, with nearly 30 years of experience across commercialisation, drug development and multiple pre-& post-product launches, with a focus in ophthalmology, immunology and immuno-oncology, leveraging cell therapy, monoclonal antibodies and multi-specific antibody modalities. He currently serves as Chief Executive Officer of Signadori Bio, a preclinical-stage biopharmaceutical company developing a next generation, off-the shelf, in vivo engineered, monocyte immunotherapy platform to treat solid tumours.

Most recently, Dr. Ho was Chief Executive Officer of Medigene AG, a German publicly listed, immuno-oncology company, developing T cell receptor (TCR) guided modalities for the treatment of solid tumours. At Medigene, Dr. Ho led the strategic pivot into the development of "off-the shelf" treatments, whilst advancing the lead autologous cell therapy programme into a successful IND and CTA approval.

Prior to this, Dr. Ho was EVP, Chief Business Officer at Connect Biopharma, a US, immunology focused biotech listed on NASDAQ (CNTB) where he supported the successful crossover financing, subsequent upsized, oversubscribed IPO, and the build out of the company’s US operations and footprint.

Dr. Ho also serves as an advisor to a number of biotech focused venture capital funds, including Sofinnova Partners (Biovelocita Strategy), New Rhein Healthcare Investors and Lupus Ventures. He is also an advisor to oncology and immunology focused biotech companies, including Antengene Corp (6996.HK) and T-Therapeutics and also serves as an independent Non-Executive Director for Peptomyc SL, a clinical stage oncology biotech company.